Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp447 | Osteoporosis: treatment | ECTS2013

Effects of sclerostin antibody and maintenance of new bone induced by sclerostin antibody in animal models

Li Xiaodong , Ominsky Michael S , Liu Min , Boyce Rogely W , Ke Hua Zhu

Treatment with sclerostin antibody (Scl-Ab) increases bone formation and strength in animal models. Here, we aimed to i) characterize the longer-term effects of Scl-Ab on bone in cynomolgus monkeys (cynos) and ovariectomized (OVX) rats and ii) test whether follow-up treatment with OPG-Fc would maintain the bone mass gains induced by Scl-Ab in OVX rats. In the cynos study, 3 to 5-year-old male cynos were treated for 6 months with weekly SC injections of vehicle (Veh), 3, 10, or...

ba0003pp355 | Osteoporosis: treatment | ECTS2014

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

Ominsky Michael S , Libanati Cesar , Boyce Rogely , Kostenuik Paul J , Baron Roland , Wagman Rachel B , Dempster David W

In clinical studies, denosumab (DMAb) administration up to 8 years is associated with continued increases in bone mineral density (BMD) and low fracture incidence despite persistently low bone turnover markers and limited iliac crest tetracycline labelling (Papapoulos 2013). We tested the hypothesis that, with persistently low bone remodelling, BMD increases may result from a non-remodelling dependent mechanism to accrue bone matrix. We examined the fluorochrome labelling patt...